医学
慢性阻塞性肺病
肺病
炎症
免疫学
嗜酸性
疾病
临床试验
重症监护医学
病理
内科学
作者
Julia W. Tripple,Jennifer McCracken,William J. Calhoun
标识
DOI:10.1016/j.iac.2017.01.009
摘要
Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.
科研通智能强力驱动
Strongly Powered by AbleSci AI